The Effect of 5-Hydroxytryptophan (5-HTP) on Satiety
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00328913 |
Recruitment Status :
Completed
First Posted : May 24, 2006
Last Update Posted : January 9, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of the study is to show evidence of the efficacy of 5-HTP to induce satiety and to reduce food intake (confirmatory study).
The primary objective of the present study is to determine:
- the effectiveness of a 5-HTP preparation on satiety markers (before intake of a meal and during the day)
The secondary objectives of the present study are to determine the effectiveness of a 5-HTP preparation on:
- food consumption (amount and composition) during a free meal (dinner);
- wellness after one week supplementation;
- the intermeal interval;
- body weight and waist-hip ratio (WHR).
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Obesity | Drug: 5-hydroxytryptophan (food supplement) | Phase 2 |

Study Type : | Interventional (Clinical Trial) |
Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Effectiveness of 5-Hydroxytryptophan on Satiety in a Randomised, Placebo Controlled, Time Blinded Study, in Overweight Women |
Study Start Date : | March 2006 |
Study Completion Date : | July 2006 |

- satiety scores (visual analog scores)
- food intake
- wellness
- intermeal interval
- body weight and waist-hip ratio

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
-
Healthy as assessed by:
- The TNO health and lifestyle questionnaire
- Physical examination
- Females aged 18 through 65 years on Day 01 of the study
- Body mass index (BMI) 25 - 32 kg/m2 (if enough subjects are available, subjects with a BMI 25 - 30 kg/m2 will be included first).
- Regular and normal Dutch eating habits (consuming mostly three main meals including breakfast) as assessed by the questionnaire on health and lifestyle
- Non-restraint eaters, defined by a score of < 3.4 on the Dutch Eating Behaviour Questionnaire
- Using oral contraceptives for > 3 months (only fixed phase)
- Voluntary participation
- Having given written informed consent
- Willing to comply with the study procedures
- Willing to agree to the use of all nameless data, including publication, and the confidential use and storage of all data for at least 15 years
- Willing to agree to the disclosure of the financial benefit of participation in the study to the authorities concerned
Exclusion Criteria:
Subjects with one or more of the following characteristics will be excluded from participation:
- Participation in any clinical trial including blood sampling and/or administration of pharmaceutical or nutritional substances up to 90 days before Day 01 of this study
- Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including blood sampling and/or oral, intravenous, or inhalatory administration of pharmaceutical or nutritional substances
- Mental status that is incompatible with the proper conduct of the study (including depression)
- Having a history of medical or surgical events that may significantly affect the study outcome, including metabolic or endocrine disease, especially diabetes type I or II; cardiovascular diseases (including hypertension); gastrointestinal diseases, including events that affect nutrient uptake or appetite; or using medication that may interfere with 5-HTP (antidepressants [selective serotonin reuptake inhibitors {SSRIs}, monoamine oxidase inhibitors {MAOIs}], migraine medication, or some hypertension medication).
- Smoking
- Having a history of drug abuse
- Claustrophobia
- Alcohol consumption > 21 units (glasses)/week
- Not willing to stop use of supplements of minerals or vitamins from screening onwards
- Reported food allergy or sensitivity (wheat, milk, eggs, nuts, etc.)
- Reported unexplained weight loss or weight gain of > 2 kg in the month prior to pre-study screening
- Practicing sports > 10 hours a week
- Reported slimming or medically prescribed diet
- Reported vegan, vegetarian, or macrobiotic lifestyle
- Pregnant or lactating or wishing to become pregnant in the period of the study
- Recent blood or plasma donation (< 1 month prior to Day 01 of the study)
- Not willing to give up blood/plasma donation during the study
- Personnel of TNO Quality of Life (located in Zeist), their partners and their first and second degree relatives
- Not having a general practitioner
- Not willing to accept information-transfer concerning participation in the study; or information regarding health, like laboratory results, findings at anamnesis or physical examination, and eventual adverse events to and from general practitioner.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00328913
Netherlands | |
TNO Quality of Life | |
Zeist, Utrecht, Netherlands, 3704HE |
Principal Investigator: | Wilrike Pasman, PhD | TNO |
ClinicalTrials.gov Identifier: | NCT00328913 |
Other Study ID Numbers: |
P6880 |
First Posted: | May 24, 2006 Key Record Dates |
Last Update Posted: | January 9, 2007 |
Last Verified: | January 2007 |
satiety food intake mood wellness weight management |
5-Hydroxytryptophan Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs |